Dr. Huang Compares Surveillance and Treatment in Kidney Cancer

Video

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

William C. Huang, MD, assistant professor in the Department of Urology at New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

Huang notes that a majority of small kidney tumors (<4 cm) are incidental findings, which may not pose a threat to patients. For these patients, surveillance may be a reasonable alternative to treatment, since cardiovascular issues are common following surgical resection.

In the population-based study, 8317 patients were examined who were treated with surgery (78%) and surveillance (22%).  The risk of dying due to kidney cancer was not significantly different between the two arms, Huang explains. Moreover, surveillance was associated with a much lower risk of developing a cardiovascular event compared to surgery (HR = 0.51; 95% CI, 0.44 — 0.60; P > .00001).

<<<

View coverage from the 2013 GU Cancers Symposium

Related Videos
Nikhil A. Gopal, MD
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD